Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility.

ABSTRACT: Glaucoma is the leading cause of irreversible blindness worldwide. Therapies for glaucoma are directed toward reducing intraocular pressure (IOP), the leading risk factor and only reliable therapeutic target via topical medications or with procedural intervention including laser or surgery. Though topical therapeutics are typically first line, less than 50% of patients take drops as prescribed. Sustained release technologies that decrease IOP for extended periods of time are being examined for clinical use. We recently identified Stanniocalcin-1, a naturally occurring hormone, as an IOP-lowering agent. Here, we show that a single injection into the anterior chamber of mice with an adeno-associated viral vector containing the transgene of stanniocalcin-1 results in diffuse and sustained exp

SUBMITTER: Roddy GW 

PROVIDER: S-EPMC9154118 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature